Literature DB >> 31801386

Restoration of Functional Full-Length Dystrophin After Intramuscular Transplantation of Foamy Virus-Transduced Myoblasts.

Jinhong Meng1,2, Nathan Paul Sweeney3, Bruno Doreste1,2, Francesco Muntoni1,2, Myra McClure3, Jennifer Morgan1,2.   

Abstract

Stem cell therapy is a promising strategy to treat muscle diseases such as Duchenne muscular dystrophy (DMD). To avoid immune rejection of donor cells or donor-derived muscle, autologous cells, which have been genetically modified to express dystrophin, are preferable to cells derived from healthy donors. Restoration of full-length dystrophin (FL-dys) using viral vectors is extremely challenging, due to the limited packaging capacity of the vectors, but we have recently shown that either a foamy viral or lentiviral vector is able to package FL-dys open-reading frame and transduce myoblasts derived from a DMD patient. Differentiated myotubes derived from these transduced cells produced FL-dys. Here, we transplanted the foamy viral dystrophin-corrected DMD myoblasts intramuscularly into mdx nude mice, and showed that the transduced cells contributed to muscle regeneration, expressing FL-dys in nearly all the muscle fibers of donor origin. Furthermore, we showed that the restored FL-dys recruited members of the dystrophin-associated protein complex and neuronal nitric oxide synthase within donor-derived muscle fibers, evidence that the restored dystrophin protein is functional. Dystrophin-expressing donor-derived muscle fibers expressed lower levels of utrophin than host muscle fibers, providing additional evidence of functional improvement of donor-derived myofibers. This is the first in vivo evidence that foamy virus vector-transduced DMD myoblasts can contribute to muscle regeneration and mediate functional dystrophin restoration following their intramuscular transplantation, representing a promising therapeutic strategy for individual small muscles in DMD.

Entities:  

Keywords:  Duchenne muscular dystrophy; codon-optimized full-length dystrophin; foamy virus; intramuscular transplantation; mdx nude mice

Mesh:

Substances:

Year:  2020        PMID: 31801386      PMCID: PMC7047098          DOI: 10.1089/hum.2019.224

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  67 in total

1.  Stem cell function, self-renewal, and behavioral heterogeneity of cells from the adult muscle satellite cell niche.

Authors:  Charlotte A Collins; Irwin Olsen; Peter S Zammit; Louise Heslop; Aviva Petrie; Terence A Partridge; Jennifer E Morgan
Journal:  Cell       Date:  2005-07-29       Impact factor: 41.582

2.  In vivo delivery of naked antisense oligos in aged mdx mice: analysis of dystrophin restoration in skeletal and cardiac muscle.

Authors:  Libero Vitiello; Nicola Bassi; Paola Campagnolo; Eva Zaccariotto; Gianluca Occhi; Alberto Malerba; Sarah Pigozzo; Carlo Reggiani; Simonetta Ausoni; Tania Zaglia; Piergiorgio Gamba; Maurizio D Baroni; Andrea P Ditadi
Journal:  Neuromuscul Disord       Date:  2008-07-03       Impact factor: 4.296

Review 3.  Advances in the Treatment of Duchenne Muscular Dystrophy: New and Emerging Pharmacotherapies.

Authors:  Andrea M Reinig; Sara Mirzaei; Daniel J Berlau
Journal:  Pharmacotherapy       Date:  2017-03-10       Impact factor: 4.705

4.  α2 and α3 helices of dystrophin R16 and R17 frame a microdomain in the α1 helix of dystrophin R17 for neuronal NOS binding.

Authors:  Yi Lai; Junling Zhao; Yongping Yue; Dongsheng Duan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-26       Impact factor: 11.205

5.  Contribution of human muscle-derived cells to skeletal muscle regeneration in dystrophic host mice.

Authors:  Jinhong Meng; Carl F Adkin; Shi-wen Xu; Francesco Muntoni; Jennifer E Morgan
Journal:  PLoS One       Date:  2011-03-09       Impact factor: 3.240

6.  High-titer foamy virus vector transduction and integration sites of human CD34(+) cell-derived SCID-repopulating cells.

Authors:  Md Nasimuzzaman; Yoon-Sang Kim; Yong-Dong Wang; Derek A Persons
Journal:  Mol Ther Methods Clin Dev       Date:  2014-06-04       Impact factor: 6.698

7.  Muscle structure influences utrophin expression in mdx mice.

Authors:  Glen B Banks; Ariana C Combs; Guy L Odom; Robert J Bloch; Jeffrey S Chamberlain
Journal:  PLoS Genet       Date:  2014-06-12       Impact factor: 5.917

8.  Lentiviral vectors can be used for full-length dystrophin gene therapy.

Authors:  John R Counsell; Zeinab Asgarian; Jinhong Meng; Veronica Ferrer; Conrad A Vink; Steven J Howe; Simon N Waddington; Adrian J Thrasher; Francesco Muntoni; Jennifer E Morgan; Olivier Danos
Journal:  Sci Rep       Date:  2017-03-06       Impact factor: 4.379

9.  Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human.

Authors:  Marcella Neri; Silvia Torelli; Sue Brown; Isabella Ugo; Patrizia Sabatelli; Luciano Merlini; Pietro Spitali; Paola Rimessi; Francesca Gualandi; Caroline Sewry; Alessandra Ferlini; Francesco Muntoni
Journal:  Neuromuscul Disord       Date:  2007-09-07       Impact factor: 4.296

10.  Rapid and Efficient Stable Gene Transfer to Mesenchymal Stromal Cells Using a Modified Foamy Virus Vector.

Authors:  Nathan Paul Sweeney; Cathy Regan; Jiahui Liu; Antonio Galleu; Francesco Dazzi; Dirk Lindemann; Charles Anthony Rupar; Myra Olga McClure
Journal:  Mol Ther       Date:  2016-05-02       Impact factor: 11.454

View more
  4 in total

1.  Optimized lentiviral vector to restore full-length dystrophin via a cell-mediated approach in a mouse model of Duchenne muscular dystrophy.

Authors:  Jinhong Meng; Marc Moore; John Counsell; Francesco Muntoni; Linda Popplewell; Jennifer Morgan
Journal:  Mol Ther Methods Clin Dev       Date:  2022-05-02       Impact factor: 5.849

2.  The Donnan-dominated resting state of skeletal muscle fibers contributes to resilience and longevity in dystrophic fibers.

Authors:  Catherine E Morris; Joshua J Wheeler; Béla Joos
Journal:  J Gen Physiol       Date:  2021-11-03       Impact factor: 4.000

Review 3.  Therapeutic Strategies for Dystrophin Replacement in Duchenne Muscular Dystrophy.

Authors:  Cedric Happi Mbakam; Gabriel Lamothe; Jacques P Tremblay
Journal:  Front Med (Lausanne)       Date:  2022-03-28

Review 4.  Strategies for Targeting Retroviral Integration for Safer Gene Therapy: Advances and Challenges.

Authors:  Kristine E Yoder; Anthony J Rabe; Richard Fishel; Ross C Larue
Journal:  Front Mol Biosci       Date:  2021-05-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.